Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD

Chronic Obstructive Pulmonary Disease, COPD Clinical Trial

Official title:
A Phase 3b, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Study to Compare Once Daily Nebulized Revefenacin With Spiriva Once Daily Delivered Via the HandiHaler® on Lung Function in Subjects With COPD and a Low PIFR

Status Completed

Clinical Trial Summary

This study is a randomized, double-blind, double-dummy, parallel group study to compare once daily nebulized Revefenacin with Spiriva once daily delivered via the HandiHaler® on lung function in subjects with COPD and a Low Peak Inspiratory Flow Rate.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Chronic Obstructive Pulmonary Disease, COPD
Low Peak Inspiratory Flow Rate (PIFR)
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Aspiration

Clinical Trial Details

NCT number	NCT03095456
Study type	Interventional
Source	Viatris Inc.
Contact
Status	Completed
Phase	Phase 3
Start date	March 27, 2017
Completion date	November 25, 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00108823` - The HERO-study: Effects of Roflumilast in Patients With COPD (Chronic Obstructive Pulmonary Disease) (BY217/M2-121)	Phase 3
Completed	`NCT03064113` - Effects of TD-4208 on FEV1 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)	Phase 2
Completed	`NCT00496470` - Evaluation of Efficacy and Safety of Symbicort® as an add-on Treatment to Spiriva® in Patients With Severe COPD.	Phase 4
Completed	`NCT02442206` - Effect of QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) on Cardiac Function in COPD Patients	Phase 4
Completed	`NCT02615795` - Tele Health Monitoring Service for Patients With Chronic Obstructive Pulmonary Disease	N/A
Completed	`NCT02449018` - A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251	Phase 2